These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19383330)

  • 21. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
    Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
    Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GPNMB expression in uveal melanoma: a potential for targeted therapy.
    Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
    Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.
    Kato Y; Ito Y; Ohishi T; Kawada M; Nakamura T; Sayama Y; Sano M; Asano T; Yanaka M; Okamoto S; Handa S; Komatsu Y; Takei J; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2020 Apr; 39(2):37-44. PubMed ID: 32182186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.
    Bhakta S; Crocker LM; Chen Y; Hazen M; Schutten MM; Li D; Kuijl C; Ohri R; Zhong F; Poon KA; Go MAT; Cheng E; Piskol R; Firestein R; Fourie-O'Donohue A; Kozak KR; Raab H; Hongo JA; Sampath D; Dennis MS; Scheller RH; Polakis P; Junutula JR
    Mol Cancer Ther; 2018 Mar; 17(3):638-649. PubMed ID: 29282299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
    Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
    J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
    Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM
    Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
    Naumovski L; Junutula JR
    Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.
    Cabaud O; Berger L; Crompot E; Adélaide J; Finetti P; Garnier S; Guille A; Carbuccia N; Farina A; Agavnian E; Chaffanet M; Gonçalves A; Charafe-Jauffret E; Mamessier E; Birnbaum D; Bertucci F; Lopez M
    Mol Cancer Ther; 2022 Jul; 21(7):1227-1235. PubMed ID: 35534238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
    Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
    Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.
    Fiorentini C; Bodei S; Bedussi F; Fragni M; Bonini SA; Simeone C; Zani D; Berruti A; Missale C; Memo M; Spano P; Sigala S
    Exp Cell Res; 2014 Apr; 323(1):100-111. PubMed ID: 24589892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
    Gerber HP; Kung-Sutherland M; Stone I; Morris-Tilden C; Miyamoto J; McCormick R; Alley SC; Okeley N; Hayes B; Hernandez-Ilizaliturri FJ; McDonagh CF; Carter PJ; Benjamin D; Grewal IS
    Blood; 2009 Apr; 113(18):4352-61. PubMed ID: 19147785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.
    Taya M; Hammes SR
    Steroids; 2018 May; 133():102-107. PubMed ID: 29097143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma.
    Pedini F; De Luca G; Felicetti F; Puglisi R; Boe A; Arasi MB; Fratini F; Mattia G; Spada M; Caporali S; Biffoni M; Giuliani A; Carè A; Felli N
    Mol Oncol; 2019 Sep; 13(9):1836-1854. PubMed ID: 31115969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycoprotein non-metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation.
    Wang C; Okita Y; Zheng L; Shinkai Y; Manevich L; Chin JM; Kimura T; Suzuki H; Kumagai Y; Kato M
    Cancer Sci; 2021 Oct; 112(10):4187-4197. PubMed ID: 34327762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
    Hanemaaijer SH; van Gijn SE; Oosting SF; Plaat BEC; Moek KL; Schuuring EM; van der Laan BFAM; Roodenburg JLN; van Vugt MATM; van der Vegt B; Fehrmann RSN
    Oral Oncol; 2018 May; 80():33-39. PubMed ID: 29706186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
    Haass NK; Sproesser K; Nguyen TK; Contractor R; Medina CA; Nathanson KL; Herlyn M; Smalley KS
    Clin Cancer Res; 2008 Jan; 14(1):230-9. PubMed ID: 18172275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.
    Kanematsu M; Futamura M; Takata M; Gaowa S; Yamada A; Morimitsu K; Morikawa A; Mori R; Hara H; Yoshida K
    Cancer Med; 2015 Sep; 4(9):1344-55. PubMed ID: 26077887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia-reperfusion injury.
    Nakano Y; Suzuki Y; Takagi T; Kitashoji A; Ono Y; Tsuruma K; Yoshimura S; Shimazawa M; Iwama T; Hara H
    Neuroscience; 2014 Sep; 277():123-31. PubMed ID: 25010402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.